Cargando…
SAT-584 Pembrolizumab-Related Graves' Disease: A Rare Adverse Effect of an Anti-PD-1 Antibody Cancer Immunotherapy
Background: Immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4 antibodies) have emerged as important anticancer therapies and are sometimes associated with thyrotoxicosis. With anti-PD-1 antibody therapy, most often this is related to destructive thyroiditis. We present a rare case of Graves’ d...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552512/ http://dx.doi.org/10.1210/js.2019-SAT-584 |